You are here
Commercialization of a Novel Therapeutic for Alzheimer's Disease
Phone: (859) 257-1412
Email: malove2@pop.uky.edu
Phone: (859) 257-1412
Email: malove2@pop.uky.edu
Address:
Type: Nonprofit College or University
ABSTRACT
Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s
diseaseADare becoming increasingly expensive and in many cases disappointingly
unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small
moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production of Ain mouse
models of AD pathology through Elkmediated transcriptional repression of presenilinbut
not presenilinAlthough our preliminary data show BNCeffectively modulatesof the main
pathologic features of AD without the adverse effects associated with current monotherapeuticsthere is a need for characterization of its basic pharmacology toxicity and for
identification of the most efficacious treatment regimen in a well characterized mouse model of
Adeposition and neuroinflammationX FAD miceIf successfulthe data obtained in this
proposal will provide necessary pharmacology safety toxicology data to de risk the drug for
potential corporate partners thus increasing the likelihood of successful commercialization
* Information listed above is at the time of submission. *